Receptors for advanced glycosylation endproducts in human brain: Role in brain homeostasis

被引:53
|
作者
Li, JJ
Dickson, D
Hof, PR
Vlassara, H [1 ]
机构
[1] Picower Inst Med Res, Lab Diabet & Aging, Manhasset, NY 11030 USA
[2] Mayo Clin Jacksonville, Jacksonville, FL 32224 USA
[3] Albert Einstein Coll Med, Dept Pathol, Div Neuropathol, Bronx, NY 10467 USA
关键词
D O I
10.1007/BF03401729
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Advanced glycation end products (AGEs) are the reactive derivatives of nonenzymatic glucose-macromolecule condensation products. Aging human tissues accumulate AGEs in an age-dependent manner and contribute to age-related functional changes in vital organs. We have shown previously that AGE scavenger receptors are present on monocyte/macrophages, lymphocytes, and other cells. However, it remains unclear whether the human brain can efficiently eliminate AGE-modified proteins and whether excessive AGEs can contribute to inflammatory changes leading to brain injury in aging. Materials and Methods: To explore the expression and characteristics of AGE-binding proteins on CNS glia components and their putative function, such as degradation of AGE-modified proteins, primary human astrocytes and human monocytes (as a microglial cell surrogate) and murine microglia (N9) cells and cell membrane extracts were used. Immunohistochemistry was used to examine the distribution of AGE-binding proteins in the human hippocampus; RT-PCR techniques were used to examine the biologic effects of AGEs and a model AGE compound, FFI, on AGE-binding protein modulation and cytokine responses of human astrocytes and monocytes. Results: Our results showed that AGE-binding proteins AGE-R-1, -R-2,, and -R-3 are present in glial cells. Western blot analyses and radiolabeled ligand binding studies show that AGE-R-1, and -R-3, from human astrocytes bind AGE-modified proteins; binding could be blocked by anti-AGE-R-1, and anti-AGE-R-3, antibodies, respectively. Immunohistochemistry showed that AGE-R-1, and -R-2, are expressed mainly in neurons; only some glial cells express these AGE-binding proteins. in contrast, AGE-R-3, was found only on those astrocytes whose positively stained foot processes extend and surround the sheath of microcapillaries. RT-PCR results showed that mRNAs of the three AGE-binding proteins are expressed constitutively in human astrocytes and monocytes, and receptor transcripts are not regulated by exogenous AGEs, the model AGE compound FFI, or phorbol ester. At the concentrations used, GM-CSF appears to be the only cytokine whose transcript and protein levels are regulated in human astrocytes by exogenous AGEs. Conclusions: The selective presence of AGE-binding proteins in pyramidal neurons and glial cells and their roles in degrading AGE-modified protein in glial cells suggest that the human brain has a mechanism(s) to clear AGE-modified proteins. Without this capacity, accumulation of AGEs extracellularly could stimulate glial cells to produce the major inflammatory cytokine GMCSF, which has been shown to be capable of up-regulating AGE-R-3,. It remains to be determined whether AGE-binding proteins could be aberrant or do cvn-regulated under certain pathological conditions, resulting in an insidious inflammatory state of the CNS in some aging humans.
引用
收藏
页码:46 / 60
页数:15
相关论文
共 50 条
  • [1] Receptors for Advanced Glycosylation Endproducts in Human Brain: Role in Brain Homeostasis
    Jenny J. Li
    Dennis Dickson
    Patrick R. Hof
    Helen Vlassara
    Molecular Medicine, 1998, 4 : 46 - 60
  • [2] Lipoprotein modification by advanced glycosylation endproducts (AGEs): Role in atherosclerosis
    Bucala, R
    TRENDS IN CARDIOVASCULAR MEDICINE, 1997, 7 (02) : 39 - 47
  • [3] THE RECEPTOR FOR ADVANCED GLYCOSYLATION ENDPRODUCTS (RAGE) HAS A CENTRAL ROLE IN CLEARANCE, TISSUE DEPOSITION, AND GENE ACTIVATION IN RESPONSE TO INFUSED ADVANCED GLYCOSYLATION ENDPRODUCTS
    SCHMIDT, AM
    BRETT, J
    MACAULAY, A
    ROSOLOWSKY, M
    SHAW, A
    STERN, D
    CIRCULATION, 1992, 86 (04) : 475 - 475
  • [4] Monocyte receptors for advanced glycosylation endproducts in patients with type 1 diabetes mellitus
    Festa, A
    Schmolzer, B
    Menzel, EJ
    Schernthaner, G
    DIABETOLOGIA, 1996, 39 : 523 - 523
  • [5] ADVANCED GLYCOSYLATION ENDPRODUCTS - ROLE IN DIABETIC AND NONDIABETIC VASCULAR-DISEASE
    BUCALA, R
    VLASSARA, H
    CERAMI, A
    DRUG DEVELOPMENT RESEARCH, 1994, 32 (02) : 77 - 89
  • [6] Functional role of nicotinic receptors in human brain
    Nordberg, A
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 19 : S4 - S5
  • [7] Chemokines and chemokine receptors in brain homeostasis
    Ransohoff, Richard M.
    Trettel, Flavia
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2015, 9
  • [8] ROLE OF ADVANCED GLYCOSYLATION ENDPRODUCTS IN MESANGIAL CELL-EXTRACELLULAR MATRIX ACCUMULATION
    PRICCI, F
    PUGLIESE, G
    OLIVA, A
    LOCURATOLO, N
    ROMANO, G
    GUIDI, B
    PUGLIESE, F
    MENE, P
    ANDREANI, D
    DIMARIO, U
    DIABETOLOGIA, 1993, 36 : A81 - A81
  • [9] THE GLYCOSYLATION OFIGF-I RECEPTORS DIFFERS IN HUMAN-BRAIN AND PLACENTA
    HEIDENREICH, KA
    GILMORE, PR
    FIGLEWICZ, DP
    FREIDENBERG, GR
    DIABETES, 1986, 35 : A60 - A60
  • [10] SOLUBLE RECEPTOR FOR ADVANCED GLYCOSYLATION ENDPRODUCTS (SRAGE) INHIBITS THE INTERACTION OF AGE-ALBUMIN WITH RECEPTORS
    SCHMIDT, AM
    MORA, R
    BRETT, J
    RYAN, J
    KUWABARA, K
    STERN, D
    CLINICAL RESEARCH, 1992, 40 (02): : A193 - A193